Activation of the PI3K-Akt pathway and its role in RCC progression was previously evaluated in a small study of 48 patients with RCC by immunohistochemistry using an antibody to p-Akt, showing that p-Akt was associated with high tumor grade and metastatic disease. Here, PIK3CA is linked to renal cell adenocarcinoma.